Division of Diabetes Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, UK.
J Eval Clin Pract. 2012 Apr;18(2):335-42. doi: 10.1111/j.1365-2753.2010.01599.x. Epub 2010 Nov 30.
Hepatocellular carcinoma (HCC) is the commonest primary hepatic malignancy and the third most common cause of cancer-related death worldwide. Incidence remains highest in the developing world and is steadily increasing across the developed world. The majority of HCC occurs on a background of cirrhosis, principally caused by two major risk factors, chronic hepatitis B and hepatitis C infection. Current diagnostic modalities, of ultrasound and α-fetoprotein, are expensive and lack sensitivity in tumour detection. Early diagnosis is integral to improved survival rates and there have been recent advances in technology that have enabled early identification of the process of hepatocarcinogenesis. This review outlines the epidemiological trends and risk factors for HCC; diagnostic techniques and current guidelines for screening and surveillance; and newer methods of screening.
肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,也是全球癌症相关死亡的第三大主要原因。发病率在发展中国家仍然最高,在发达国家也在稳步上升。大多数 HCC 发生在肝硬化的背景下,主要由两个主要危险因素引起,即慢性乙型肝炎和丙型肝炎感染。目前的诊断方法,包括超声和甲胎蛋白,既昂贵又缺乏肿瘤检测的敏感性。早期诊断是提高生存率的关键,最近在技术上取得了一些进展,使早期识别肝癌发生过程成为可能。本文综述了 HCC 的流行病学趋势和危险因素;诊断技术和目前的筛查和监测指南;以及新的筛查方法。